triazoles has been researched along with cyc 202 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akli, S; Biernacka, A; Bui, T; Hunt, KK; Keyomarsi, K; Moulder, S; Tucker, SL; Wingate, H | 1 |
| Abrol, R; Goddard, WA; Kudo, W; Nair, N; Reddy, VP; Smith, MA | 1 |
2 other study(ies) available for triazoles and cyc 202
| Article | Year |
|---|---|
Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclin E; Drug Resistance, Neoplasm; Female; G1 Phase; Humans; Letrozole; Molecular Weight; Nitriles; Postmenopause; Prognosis; Purines; Roscovitine; Triazoles | 2010 |
Novel purine-based fluoroaryl-1,2,3-triazoles as neuroprotecting agents: synthesis, neuronal cell culture investigations, and CDK5 docking studies.
Topics: Animals; Cell Cycle; Cells, Cultured; Cyclin-Dependent Kinase 5; Flavonoids; Fluorine; Hippocampus; Humans; Hydrogen Bonding; Mice; Models, Molecular; Molecular Structure; Neuroprotective Agents; Piperidines; Protein Kinase Inhibitors; Purines; Roscovitine; Triazoles | 2011 |